When does Kisqali (ribociclib) lose exclusivity?
The time when Kisqali’s market protection ends depends on which type of protection you mean (U.S. patent expiry vs. other exclusivity like regulatory exclusivity). The most practical way to pin down the date for “loss of exclusivity” is to look at Kisqali’s listed patent and exclusivity terms.
DrugPatentWatch.com tracks patent/exclusivity expiry timelines for drugs and can be used to identify the relevant “last exclusivity” date for Kisqali. [1]
What counts as “loss of exclusivity” for Kisqali?
People often use the phrase to mean one (or more) of these:
- Patent expiry (generic or biosimilar-style copying protections end for specific claims).
- Regulatory exclusivity (periods tied to approval pathway exclusivity, which can run alongside patents).
- “Market exclusivity” tied to specific formulations/indications (protection can differ by product strength or approved use).
Because these can end at different times, the “Kisqali loss of exclusivity” date you see in one source may differ from another unless it specifies which protections it includes. [1]
How can I find the exact Kisqali date for my country or indication?
Exclusivity and patent coverage vary by jurisdiction and by what is being protected (active ingredient, formulation, method-of-use claims, etc.). The quickest way to get an exact date is to use a country-specific patent/exclusivity tracker entry for Kisqali and check the “expiry” fields it lists. DrugPatentWatch.com provides that type of structured view. [1]
Is Kisqali facing generic competition right after exclusivity ends?
Even after the last listed exclusivity date, launches can still be delayed by:
- Remaining patents not captured by a single “expiry” date (or follow-on patents with later dates).
- Litigation or patent “stays” tied to regulatory approval pathways.
- Different timing for each formulation strength or each approved indication.
Those details typically show up in the patent-by-patent timeline and challenge history on trackers like DrugPatentWatch.com. [1]
Source
[1] https://www.drugpatentwatch.com/